Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer

Background: Non–small cell lung cancer (NSCLC) is among the major health problems around the world. Reliable biomarkers for NSCLC are still needed in clinical practice. We aimed to develop a novel ferroptosis- and immune-based index for NSCLC.Methods: The training and testing datasets were obtained...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang Teng, Bo Wang, Desi Shang, Ning Yang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	NSCLC biomarkers bioinformatics analysis microenvironment non–small cell lung cancer immune prognosis Genetics QH426-470
Acceso en línea:	https://doaj.org/article/d13b02dce62e49b196a898db2e538981
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d13b02dce62e49b196a898db2e538981
record_format	dspace
spelling	oai:doaj.org-article:d13b02dce62e49b196a898db2e5389812021-12-01T17:03:04ZIdentification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer1664-802110.3389/fgene.2021.764869https://doaj.org/article/d13b02dce62e49b196a898db2e5389812021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fgene.2021.764869/fullhttps://doaj.org/toc/1664-8021Background: Non–small cell lung cancer (NSCLC) is among the major health problems around the world. Reliable biomarkers for NSCLC are still needed in clinical practice. We aimed to develop a novel ferroptosis- and immune-based index for NSCLC.Methods: The training and testing datasets were obtained from TCGA and GEO databases, respectively. Immune- and ferroptosis-related genes were identified and used to establish a prognostic model. Then, the prognostic and therapeutic potential of the established index was evaluated.Results: Intimate interaction of immune genes with ferroptosis genes was observed. A total of 32 prognosis-related signatures were selected to develop a predictive model for NSCLC using LASSO Cox regression. Patients were classified into the high- and low-risk group based on the risk score. Patients in the low-risk group have better OS in contrast with that in the high-risk group in independent verification datasets. Besides, patients with a high risk score have shorter OS in all subgroups (T, N, and M0 subgroups) and pathological stages (stage I, II, and III). The risk score was positively associated with Immune Score, Stromal Score, and Ferroptosis Score in TCGA and GEO cohorts. A differential immune cell infiltration between the high-risk and the low-risk groups was also observed. Finally, we explored the significance of our model in tumor-related pathways, and different enrichment levels in the therapeutic pathway were observed between the high- and low-risk groups.Conclusion: The present study developed an immune and ferroptosis-combined index for the prognosis of NSCLC.Yang TengBo WangDesi ShangNing YangNing YangFrontiers Media S.A.articleNSCLCbiomarkersbioinformatics analysismicroenvironment non–small cell lung cancerimmuneprognosisGeneticsQH426-470ENFrontiers in Genetics, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	NSCLC biomarkers bioinformatics analysis microenvironment non–small cell lung cancer immune prognosis Genetics QH426-470
spellingShingle	NSCLC biomarkers bioinformatics analysis microenvironment non–small cell lung cancer immune prognosis Genetics QH426-470 Yang Teng Bo Wang Desi Shang Ning Yang Ning Yang Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
description	Background: Non–small cell lung cancer (NSCLC) is among the major health problems around the world. Reliable biomarkers for NSCLC are still needed in clinical practice. We aimed to develop a novel ferroptosis- and immune-based index for NSCLC.Methods: The training and testing datasets were obtained from TCGA and GEO databases, respectively. Immune- and ferroptosis-related genes were identified and used to establish a prognostic model. Then, the prognostic and therapeutic potential of the established index was evaluated.Results: Intimate interaction of immune genes with ferroptosis genes was observed. A total of 32 prognosis-related signatures were selected to develop a predictive model for NSCLC using LASSO Cox regression. Patients were classified into the high- and low-risk group based on the risk score. Patients in the low-risk group have better OS in contrast with that in the high-risk group in independent verification datasets. Besides, patients with a high risk score have shorter OS in all subgroups (T, N, and M0 subgroups) and pathological stages (stage I, II, and III). The risk score was positively associated with Immune Score, Stromal Score, and Ferroptosis Score in TCGA and GEO cohorts. A differential immune cell infiltration between the high-risk and the low-risk groups was also observed. Finally, we explored the significance of our model in tumor-related pathways, and different enrichment levels in the therapeutic pathway were observed between the high- and low-risk groups.Conclusion: The present study developed an immune and ferroptosis-combined index for the prognosis of NSCLC.
format	article
author	Yang Teng Bo Wang Desi Shang Ning Yang Ning Yang
author_facet	Yang Teng Bo Wang Desi Shang Ning Yang Ning Yang
author_sort	Yang Teng
title	Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
title_short	Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
title_full	Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
title_fullStr	Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
title_full_unstemmed	Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
title_sort	identification and validation of an immune and ferroptosis-combined index for non–small cell lung cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d13b02dce62e49b196a898db2e538981
work_keys_str_mv	AT yangteng identificationandvalidationofanimmuneandferroptosiscombinedindexfornonsmallcelllungcancer AT bowang identificationandvalidationofanimmuneandferroptosiscombinedindexfornonsmallcelllungcancer AT desishang identificationandvalidationofanimmuneandferroptosiscombinedindexfornonsmallcelllungcancer AT ningyang identificationandvalidationofanimmuneandferroptosiscombinedindexfornonsmallcelllungcancer AT ningyang identificationandvalidationofanimmuneandferroptosiscombinedindexfornonsmallcelllungcancer
_version_	1718404778919198720

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer

Ejemplares similares